An Aethlon Medical-developed medical device designed to eliminate viral pathogens from the circulatory system of infected patients has passed a milestone validation on its capacity to capture the Middle East Respiratory Syndrome Coronavirus.
Aethlon said Thursday it has completed multiple milestones under a Defense Advanced Research Projects Agency contract such as the Hemopurifier stage and 29 other checkpoints under DARPA’s Dialysis-Like Therapeutics program.
Jim Joyce, Aethlon Medical chairman and CEO, said that the accomplishment along with other DARPA milestones helps the company reinforce a belief in the Hemopurifier as a broad-spectrum candidate that will treat viruses not addressed through antiviral drugs.
Aethlon added the milestones under DARPA’s DLT program helped contribute to the growth of Hemopurifier manufacturing processes and capacity, and expanded the device’s broad-spectrum virus capture validations.
Hemopurifier has conducted tests on captures of different strains, species and families of viral pathogens through human and in vitro validation studies and is under development in Food and Drug Administration-approved studies as a treatment countermeasure against viral pathogens.